tradingkey.logo
tradingkey.logo
Search

Zai Lab Ltd

ZLAB
Add to Watchlist
18.270USD
+0.060+0.33%
Close 07-31 16:00ETQuotes delayed by 15 min
2.07BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+0.33%

5 Days

-4.94%

1 Month

-4.60%

6 Months

+10.06%

Year to Date

+3.57%

1 Year

-50.38%

Key Figures
18.230Open
18.770High
353.71KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.32%Turnover Ratio
18.210Prev. Close
17.970Low
4.02MTurnover
LossP/E Static
3.06P/B
0.00%Div Yield TTM
-15.70%ROA
44.34052wk High
0.57Volume Ratio
-257.10MNet Profit
111.02MShares
-1.6151EPS TTM
0.81Beta
-24.19%ROE
15.96052wk Low
4.39%Amplitude
61.72%Gross Margin
2.07BMarket Cap
-2.21Reward/Risk
2.06%Risk Rate

TradingKey Stock Score of Zai Lab Ltd

Currency: USD Updated: 2026-07-31

Key Insights

Zai Lab Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.88.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zai Lab Ltd's Score

Industry at a Glance

Industry Ranking
65 / 155
Overall Ranking
138 / 4281
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Zai Lab Ltd Highlights

StrengthsRisks
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 72.52% year-on-year.
Fairly Valued
The company’s latest PE is -11.31, at a medium 3-year percentile range.
Held by Ron Baron
Star Investor Ron Baron holds 1.67M shares of this stock.

Analyst Rating

Based on 12 analysts
Buy
Current Rating
33.876
Target Price
+85.42%
Upside Space

Zai Lab Ltd News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 12 analysts
Buy
Current Rating
33.876
Target Price
+85.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Zai Lab Ltd
ZLAB
12
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32

Indicators

Indicators
Sell(1)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.543
Neutral
RSI(14)
39.992
Neutral
STOCH(KDJ)(9,3,3)
11.245
Oversold
ATR(14)
0.787
Low Volatility
CCI(14)
-98.328
Neutral
Williams %R
88.247
Oversold
TRIX(12,20)
0.075
Sell
StochRSI(14)
22.429
Buy
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
18.410
Sell
MA10
19.245
Sell
MA20
19.571
Sell
MA50
18.615
Sell
MA100
19.495
Sell
MA200
19.937
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Zai Lab Ltd Info

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Ticker SymbolZLAB
CompanyZai Lab Ltd
CEODu (Ying)
Websitehttps://www.zailaboratory.com/

Shareholders

Shareholders
Shareholders
Proportion
RTW Investments L.P.
6.19%
RA Capital Management, LP
5.11%
Norges Bank Investment Management (NBIM)
3.42%
Frazier Life Sciences Management, L.P.
1.69%
ClearBridge Investments, LLC
1.61%
Other
81.97%

FAQs

What is the current price of Zai Lab Ltd (ZLAB)?

The current price of Zai Lab Ltd (ZLAB) is 18.27.

What is the symbol of Zai Lab Ltd?

The ticker symbol of Zai Lab Ltd is ZLAB.

What is the 52-week high of Zai Lab Ltd?

The 52-week high of Zai Lab Ltd is 44.34.

What is the 52-week low of Zai Lab Ltd?

The 52-week low of Zai Lab Ltd is 15.96.

What is the market capitalization of Zai Lab Ltd?

The market capitalization of Zai Lab Ltd is 2.03B.

Is Zai Lab Ltd (ZLAB) currently rated as Buy, Hold, or Sell?

According to analysts, Zai Lab Ltd (ZLAB) has an overall rating of Buy, with a price target of 33.88.

What is the Earnings Per Share (EPS TTM) of Zai Lab Ltd (ZLAB)?

The Earnings Per Share (EPS TTM) of Zai Lab Ltd (ZLAB) is -1.60.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.